However, other FASN inhibitors such as orlistat, which has been shown to reduce FASN activity in non-small cell lung cancer [41], are readily available for clinical use, albeit issues of that drug’s low cell permeability and solubility, lack of selectivity [42], and poor metabolic stability [43] may need to be overcome, perhaps through use of orlistat metabolites. The gene discussed is FASN; the disease is non-small cell lung carcinoma.